RE:10 patients early 2021 for 25 for Breakthrough Designation To date 16 patients have been treated in Study II. The Company has now launched 5 CSS’s in Canada and 6 in the US for patient enrollment and treatment under Study II clinical study guideline.
Shawn Shirazi PhD, Chief Executive Officer, Theralase®, stated, “It is exciting to see Theralase hit its target of having 6 US clinical sites on board in 1Q 2021. It is truly uplifting to be working on the details of getting patients enrolled and treated at these sites. Theralase is another step closer in achieving its next milestone of enrolling and treating 9 additional patients in early 2021 to meet the target of 25 patients for potential Breakthrough Designation.”
March 25, 2021, Theralase® Technologies Inc
https://theralase.com/theralase-launches-sixth-clinical-study-site-in-the-us-for-phase-ii-bladder-cancer-clinical-study/
floatinketucky wrote: Shawn Shirazi, PhD, Chief Executive Officer, Theralase®, stated, "Each CSS Theralase launches for Study II will aid in our objective of enrolling and treating 10 patients in early 2021 to achieve a total of 25 patients for potential Breakthrough Designation Approval and approximately 75 to 100 additional patients in 2021 / 2022."